Ranolazine attenuates behavioral signs of neuropathic pain

Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

[1]  R. Gil‐Gouveia,et al.  Neuropsychiatric Side-Effects of Lidocaine: Examples from the Treatment of Headache and a Review , 2009, Cephalalgia : an international journal of headache.

[2]  J. Shryock,et al.  Block of Tetrodotoxin-sensitive, Nav1.7, and Tetrodotoxin-resistant, Nav1.8, Na+ channels by Ranolazine , 2008, Channels.

[3]  B. Taylor,et al.  Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain , 2008, PAIN®.

[4]  G. Tenderich,et al.  Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. , 2008, Journal of molecular and cellular cardiology.

[5]  R. Kloner,et al.  Late sodium current inhibition as a new cardioprotective approach. , 2008, Journal of molecular and cellular cardiology.

[6]  G. Wang,et al.  State- and Use-Dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-Gated Na+ Channel Isoforms by Ranolazine , 2008, Molecular Pharmacology.

[7]  S. Waxman,et al.  Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. , 2007, The Journal of clinical investigation.

[8]  Sulayman D. Dib-Hajj,et al.  From genes to pain: Nav1.7 and human pain disorders , 2007, Trends in Neurosciences.

[9]  Ngoc Phuoc An Vo,et al.  Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain , 2007, Pain.

[10]  D. Pham,et al.  Ranolazine: a novel agent that improves dysfunctional sodium channels , 2007, International journal of clinical practice.

[11]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[12]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[13]  S. Waxman.  Neurobiology: A channel sets the gain on pain , 2006, Nature.

[14]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[15]  C. Marx,et al.  Mechanism of action of ranolazine. , 2006, Archives of internal medicine.

[16]  J. Shryock,et al.  Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine , 2006, Heart.

[17]  D. Nash.  The case for medical treatment in chronic stable coronary artery disease. , 2005, Archives of internal medicine.

[18]  A. M. Rush,et al.  Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. , 2005, Brain : a journal of neurology.

[19]  C. Bollensdorff,et al.  Expression pattern of neuronal and skeletal muscle voltage‐gated Na+ channels in the developing mouse heart , 2005, Journal of Physiology.

[20]  G. Forlani,et al.  Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Gould,et al.  Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. , 2004, The journal of pain : official journal of the American Pain Society.

[22]  Xiao-jun Xu,et al.  A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain. , 2003, European journal of pharmacology.

[23]  M. Devor,et al.  Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  M. Devor,et al.  Oscillatory mechanism in primary sensory neurones. , 2002, Brain : a journal of neurology.

[25]  M. Zimmermann,et al.  Pathobiology of neuropathic pain. , 2001, European journal of pharmacology.

[26]  C. Woolf,et al.  Spared nerve injury: an animal model of persistent peripheral neuropathic pain , 2000, Pain.

[27]  H. Gould,et al.  A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain , 2000, Brain Research.

[28]  M. Devor,et al.  Membrane Potential Oscillations in Dorsal Root Ganglion Neurons: Role in Normal Electrogenesis and Neuropathic Pain , 1999, The Journal of Neuroscience.

[29]  P W Gage,et al.  Hypoxia increases persistent sodium current in rat ventricular myocytes. , 1996, The Journal of physiology.

[30]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[31]  P. Gage,et al.  Tetrodotoxin-sensitive inactivation-resistant sodium channels in pacemaker cells influence heart rate , 2006, Pflügers Archiv.

[32]  M. Devor.  Sodium channels and mechanisms of neuropathic pain. , 2006, The journal of pain : official journal of the American Pain Society.

[33]  M. Koltzenburg.  Afferent mechanisms mediating pain and hyperalgesias in neuralgia , 1996 .